
Immix Biopharma – Q326 update: NXC-201 enters its next phase NXC-201 delivers 89% CR rate (potential 98%) across 45 r/r ALA patients. BLA targeted mid-2027; $336m cash provides runway to mid-2028. Valuation $16.3/sh. Full analysis edisongroup.com/research/q32… $IMMX @Immixbiopharma
